Investor Presentation: First Nine Months of 2020
17
Investor presentation
First nine months of 2020
Strategic aspirations 2025
Purpose and
sustainability
لا
Commercial
execution
•
•
Being respected for adding value to society
•
Progress towards zero environmental impact
Ensure distinct core capabilities and evolve culture
•
•
Strengthen Diabetes leadership - aim at global
value market share of more than 1/3
Strengthen Obesity leadership and double current
sales¹
• Secure a sustained growth outlook for Biopharm
Financials
therapeutic focus
Innovation and
O||||||
.
•
•
Further raise the innovation-bar for diabetes
treatment
Develop a leading portfolio of superior treatment
solutions for obesity
Strengthen and progress the Biopharm pipeline
Establish presence in Other serious chronic diseases
focusing on CVD, NASH and CKD
Deliver solid sales and operating profit growth
•
Deliver 6-10% sales growth in IO
•
Transform 70% of sales in the US²
Drive operational efficiencies across the value chain to
enable investments in future growth assets
Deliver free cash flow to enable attractive capital
allocation to shareholders
1 Based on reported sales in 2019, 2 From 2015 to 2022. IO: International Operations; CVD: Cardiovascular disease; NASH: Non-alcoholic steatohepatitis; CKD: Chronic kidney disease.
Novo NordiskⓇView entire presentation